1.
Hepatitis Monthly. 2004; 4 (7): 75-78
en Inglés
| IMEMR
| ID: emr-203600
RESUMEN
Background and aims: pegylation of interferon alfa-2a is a new modality for treatment of chronic hepatitis C. This clinical trial was conducted to evaluate the efficacy and safety of PEG IFN in combination with ribavirin in CHC patients
Methods: fifty-seven patients with HGV RNA in serum, persistently elevated ALT and chronic C hepatitis on liver biopsy enrolled to this study. The patients received PEG IFN 180 micg per week plus ribavirin 10- 15 mg/kg per day
Results: HCV RNA was negative in 37 patients [74%] after three months of beginning of study [EVR] and SVR occurred in 50% of all patients
Conclusion: peginterferon alfa-2a plus ribavirin is safe and effective in treatment of naive patients and relapses